A share price of Theravance Biopharma Inc [TBPH] is currently trading at $10.47, up 8.27%. An important factor to consider is whether the stock is rising or falling in short-term value. The TBPH shares have gain 24.05% over the last week, with a monthly amount glided 9.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on August 06, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $10 from $15. Previously, BTIG Research started tracking the stock with Buy rating on April 12, 2024, and set its price target to $21. On January 08, 2024, downgrade downgraded it’s rating to In-line. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $12 on May 23, 2022. JP Morgan upgraded its rating to a Neutral but $12 remained the price target by the analyst firm on November 05, 2021. JP Morgan downgraded its rating to Underweight for this stock on September 15, 2021, but kept the price target unchanged to $7. In a note dated August 25, 2021, Morgan Stanley downgraded an Underweight rating on this stock and revised its target price from $27 to $14.
Theravance Biopharma Inc experienced fluctuations in its stock price throughout the past year between $7.44 and $10.44. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $10.47 at the most recent close of the market. An investor can expect a potential return of 19.39% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
Trailing Twelve Months sales for Theravance Biopharma Inc [NASDAQ:TBPH] were 63.19M which represents 7.49% growth. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.65%, Pretax Profit Margin comes in at -0.64%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.25 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.76 points at the first support level, and at 9.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.04, and for the 2nd resistance point, it is at 11.61.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Theravance Biopharma Inc [NASDAQ:TBPH] is 4.97. On the other hand, the Quick Ratio is 4.97, and the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 8.15, the price to book ratio is 2.77.
Transactions by insiders
Recent insider trading involved Farnum Rhonda, SVP, COMM & MEDICAL AFFAIRS, that happened on Jan 21 ’25 when 4000.0 shares were sold. Officer, RHONDA FARNUM completed a deal on Jan 21 ’25 to buy 4000.0 shares. Meanwhile, SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold 4000.0 shares on Nov 11 ’24.
